TIME-2b Disappointed: Aerpio’s Lead Product Fails In Diabetic Retinopathy

As its lead product fails at Phase IIb in diabetic retinopathy, Aerpio’s attentions turn to its other potential indications, but investors will need more convincing that this strategy will pay dividends.